Key Pharmacokinetic Processes

Why This Matters

Pharmacokinetics answers a fundamental question: what does the body do to the drug? You need to predict how drugs behave once they enter a patient: how quickly they'll work, how long they'll last, and why some patients need different doses than others. These concepts form the quantitative backbone of drug therapy, connecting abstract chemistry to real clinical decisions about dosing intervals, route selection, and patient safety.

The four core processes, absorption, distribution, metabolism, and excretion (ADME), don't exist in isolation. They interact dynamically, and exam questions will push you to think about how changes in one process cascade through the others. Don't just memorize definitions. Know what each parameter tells you about a drug's behavior and when you'd adjust therapy based on that information.

---

The ADME Framework: How Drugs Move Through the Body

These four processes describe the complete journey of a drug molecule from administration to elimination. Each step represents a potential point of variability between patients and a target for drug interactions.

Absorption

Absorption is the process by which a drug moves from its administration site into the bloodstream. It determines how much drug is available to produce effects and how quickly those effects begin.

• Rate-limiting factors include drug formulation, GI pH, blood flow to the absorption site, and surface area. Oral drugs face the most barriers because they must cross the GI epithelium and survive the gut environment.
• IV administration bypasses absorption entirely, providing 100% availability with immediate onset. That's why it's the reference standard for bioavailability comparisons.

Distribution

Once a drug reaches the bloodstream, distribution describes how it moves from blood into tissues, fluids, and ultimately to its site of action.

• Protein binding to albumin (for acidic drugs) and alpha-1 acid glycoprotein (for basic drugs) limits the free drug available for effect. Only unbound drug is pharmacologically active, can cross membranes, and can be eliminated.
• Tissue permeability varies dramatically. The blood-brain barrier excludes most drugs unless they're small and lipophilic, while highly perfused organs (heart, liver, kidneys) receive drug rapidly.

Metabolism

Metabolism (also called biotransformation) converts lipophilic drugs into more water-soluble metabolites that the body can eliminate. The liver is the primary site, with cytochrome P450 (CYP450) enzymes doing most of the work.

• Phase I reactions (oxidation, reduction, hydrolysis) introduce or expose a functional group. These often create metabolites that are still pharmacologically active. For example, codeine is converted by CYP2D6 to morphine, which is actually the active analgesic.
• Phase II reactions (conjugation with glucuronic acid, sulfate, acetyl groups, etc.) typically inactivate drugs and make them much more water-soluble for renal excretion.
• Drug interactions frequently occur at this step. Enzyme inducers (like rifampin or carbamazepine) speed up metabolism, reducing drug levels. Enzyme inhibitors (like ketoconazole or erythromycin) slow metabolism, raising drug levels and increasing toxicity risk.

Excretion

Excretion is the irreversible removal of drug or metabolites from the body. The kidneys handle most of this work through three mechanisms:

1. Glomerular filtration of unbound drug
2. Active tubular secretion (carrier-mediated transport into the tubular lumen)
3. Tubular reabsorption (passive diffusion back into blood, which reduces net excretion)

• Alternative routes include biliary excretion (with potential enterohepatic recirculation, which can prolong drug effects), pulmonary exhalation (relevant for volatile anesthetics), and minor losses through sweat and saliva.
• Kidney function directly impacts dosing. Reduced GFR requires dose adjustments to prevent drug accumulation and toxicity. This is why creatinine clearance is checked before prescribing renally eliminated drugs like gentamicin or vancomycin.

---

Quantifying Drug Availability

These parameters help you calculate and predict how much drug actually reaches its target. They're essential for dosing calculations and for understanding why the same dose produces different effects in different patients.

Bioavailability

Bioavailability (abbreviated F) is the fraction of an administered dose that reaches systemic circulation in active form. It's expressed as a percentage or decimal, with IV administration defined as 100% (F = 1).

• First-pass metabolism is the primary reason oral bioavailability falls below 100%. Some drugs lose over 90% of their dose before reaching circulation. Poor absorption from the GI tract can also reduce F.
• Dosing implications are direct: switching routes requires recalculation. A drug with 50% oral bioavailability needs twice the oral dose to match an IV dose. For example, if 5 mg IV produces the desired effect, you'd need 10 mg orally to deliver the same amount to the bloodstream.

First-Pass Effect

The first-pass effect refers to pre-systemic metabolism that occurs when orally administered drugs pass through the gut wall and liver before reaching systemic circulation.

• High extraction drugs like morphine, propranolol, and nitroglycerin have dramatically reduced oral bioavailability because of this. Nitroglycerin, for instance, has less than 1% oral bioavailability, which is why it's given sublingually (absorbed directly into the systemic venous system, bypassing the liver).
• Bypassing strategies include sublingual, transdermal, rectal (lower rectum drains into the inferior vena cava, not the portal vein), and parenteral routes. All of these avoid or reduce portal circulation exposure.

---

Parameters That Guide Dosing Decisions

These calculated values translate pharmacokinetic theory into practical dosing. Master these relationships and you can predict how dose adjustments will affect drug levels.

Volume of Distribution

The volume of distribution ($V_d$) is a theoretical volume representing the apparent space a drug would occupy if it were distributed uniformly at the same concentration measured in plasma.

$V_d = \frac{\text{Dose}}{C_0}$

where $C_0$ is the initial plasma concentration right after dosing (before any elimination occurs).

• Interpretation matters more than the number itself. A small $V_d$ (around 3-5 L, roughly plasma volume) suggests the drug stays in the bloodstream, often because it's highly protein-bound (e.g., warfarin). A large $V_d$ (>40 L, exceeding total body water of ~42 L) indicates extensive tissue binding or sequestration in fat (e.g., chloroquine, with a $V_d$ of over 200 L).
• Loading dose calculations depend directly on $V_d$: $\text{Loading Dose} = V_d \times C_{\text{target}}$. Drugs with large volumes of distribution require larger loading doses to fill that tissue reservoir and achieve therapeutic plasma levels quickly.

Half-Life

Half-life ($t_{1/2}$) is the time required for the plasma concentration to drop by 50%.

$t_{1/2} = \frac{0.693 \times V_d}{CL}$

This equation reveals something important: half-life is not a pure measure of elimination. It depends on both distribution ($V_d$) and clearance ($CL$). A drug can have a long half-life because it distributes widely into tissues, even if the body clears it efficiently.

• The 4-5 half-life rule applies in two directions. With repeated dosing, a drug reaches steady state after about 4-5 half-lives. After stopping a drug, it's essentially eliminated (~97%) after 4-5 half-lives. This rule holds regardless of dose size or dosing interval.
• Half-life determines dosing frequency. A drug with a 24-hour half-life can be dosed once daily; a drug with a 4-hour half-life may need dosing every 4-6 hours to avoid large swings in plasma concentration.

Clearance

Clearance ($CL$) is the volume of plasma completely cleared of drug per unit time (expressed in L/hr or mL/min). It's the single most important parameter for determining maintenance dose.

$\text{Dose rate} = CL \times C_{ss}$

where $C_{ss}$ is the desired steady-state concentration.

• Organ-specific clearance (hepatic, renal) can be measured separately. Total systemic clearance equals the sum of all elimination pathways: $CL_{\text{total}} = CL_{\text{renal}} + CL_{\text{hepatic}} + CL_{\text{other}}$.
• Higher clearance means the body eliminates drug faster, so you need a higher dose rate to maintain the same steady-state concentration.

---

Achieving Therapeutic Goals

These concepts connect individual parameters to the ultimate goal: maintaining effective drug concentrations over time.

Steady-State Concentration

Steady state ($C_{ss}$) is the equilibrium point where the rate of drug input equals the rate of elimination. This is the target for chronic therapy.

• Time to steady state equals 4-5 half-lives regardless of dose or dosing interval. You cannot shorten this timeline by giving larger maintenance doses (that just raises the final $C_{ss}$). The only way to reach therapeutic levels faster is to give a loading dose.
• Fluctuation between peak ($C_{\text{max}}$) and trough ($C_{\text{min}}$) levels depends on the dosing interval relative to half-life. Dosing more frequently (or using a continuous IV infusion) produces smoother levels with less fluctuation. This matters most for drugs with a narrow therapeutic index, where small swings can mean the difference between efficacy and toxicity.

---

Quick Reference Table

---

Self-Check Questions

1. A drug has a half-life of 6 hours. How long will it take to reach steady state with regular dosing, and what percentage of steady state is achieved after 3 half-lives?

2. Compare volume of distribution and clearance: which parameter determines loading dose, which determines maintenance dose, and why?

3. Two drugs have identical clearance values, but Drug A has a $V_d$ of 10 L while Drug B has a $V_d$ of 200 L. Which has the longer half-life, and how would their dosing frequencies differ?

4. A patient with severe liver disease is prescribed a drug with high first-pass metabolism. Would you expect the oral bioavailability to increase or decrease compared to a healthy patient? Explain the mechanism.

5. If a patient on chronic phenytoin therapy develops toxicity after starting a new medication, which pharmacokinetic process and parameter should you focus on, and what specific mechanism would you describe?